The PPH stocks are doing well. The iShares US Pharmaceutical ETF stock (IHE), which is closely monitored, has risen 16.5%. This has slightly beaten the S&P 500, which rose by 16.3%.
VanEck Vectors Pharmaceutical ETF PPH is one of the top performing firms within the pharmaceutical industry. It has grown by more than 20%. The article examines some of the best stocks, such as Bristol-Myers Squibb BMY (BMY), Pfizer PFE (PFE), AbbVie.
BMY
Bristol-Myers Squibb, a major pharmaceutical company in America. The company focuses on industries such as oncology and hematology. It also specializes in immunology, cardiovascular disease, neurosciences, and cardiovascular diseases.
The company’s business has been growing organically as well through acquisitions. Centene was its biggest acquisition, for which the company paid $74 billion. It bought Mirati most recently. This helped expand the oncology division.
Bristol-Myers’ most recent financial report showed that it made $12 billion in revenue for the quarter, while GAAP earnings were down to 83 cents. The majority of the company’s revenues came from Elquis and Opdivo, which brought in $2.5 Billion and $1.4 Billion respectively.
BMY has a reputation as a solid pharma firm because of its diversified business portfolio, and the safe dividends it pays out. The yield is 4.80%.
Bristol-Myers Squibb’s stock did not do well over the last few months. It dropped from $75 in 2022 down to $50 or less in July. Recenty, though, the stock increased by 28%, trading at $50. The stock has returned to the Fibonacci Retracement of 61.8%.
BMY also formed a death-cross pattern in December. This explains the reason why the shares retreated throughout the majority of the year. It has also formed a popular bullish chart pattern called a flag chart.
The outlook is therefore moderately positive. Next, we will be watching the point of the 200-day average at $55.
Bristol-Myers Squibb Stock
Pfizer | PFE
Pfizer ranks as one of the top pharmaceutical companies worldwide. Pfizer’s popularity soared when the Covid-19 Pandemic hit, as the company became one of top vaccine sellers.
Pfizer has also been known to destroy value over time. Over the last two decades the company spent more than $300 billion on acquisitions. This includes the purchase of Warner-Lambert for $90 billion and Pharmacia for $60 billion. Wyeth was acquired for $68 Billion and Hospira $17 Billion. Pfizer’s market capitalization is over $161 Billion today.
Pfizer’s stock has also suffered in recent years due to the Covid operation. The stock price dropped from $54 to under $30 in 2021. In October of last year it formed a death-cross pattern on its weekly chart, which led to further downside.
Pfizer’s stock is trading at $28.50 after recent results. It is still below both the 200-week and 50-week moving averages. This means that the bears remain in charge.
The outlook is therefore moderately negative. Next, we should watch the low for the entire year of $24.56, or about 13.7% lower than the current price.
Pfizer stock
AbbVie | ABBV
AbbVie has, unlike BMY or Pfizer been one of Wall Street’s most beloved pharma firms. The stock has reached a new record of nearly $200. This means that the company has increased by more than 240% over the past five years. This year, it has also risen by 27%.
AbbVie’s business is focused on areas such as immunology, neurology, oncology and eyecare. Humira is its most significant product. It’s a drug that treats arthritis and Crohn’s disease.
Recently, it announced its plans to develop a drug for weight loss in order to compete against the likes Novo Nordisk or Eli Lilly.
AbbVie is doing better than BMW or Pfizer, because its organic growth was the majority. It has made billions of dollars in acquisitions but hasn’t been aggressive. AbbVie’s biggest acquisitions include the $63 Billion buyouts of Allergan, and the $21 Billion buyouts of Pharmacyclics. Recently, it bought ImmunoGen for $10 billion.
AbbVie reported a revenue of $14.6 billion for the second quarter, compared to $13.8 billion the prior quarter. Net earnings fell sharply from $1.3 billion to $1.46 billion.
After earnings, the daily chart shows ABBV’s share price peaked around $199.78. It has since retreated to about $192. The price has been above moving averages for a long time, indicating that the retreat was part of ABBV’s profit-taking.
AbbVie is also above $180, the level of resistance that was its high point for March. The stock’s move above this level invalidated the previous double-top formation.
AbbVie’s stock, therefore, has greater upside potential in the future. There is the risk of a pullback as the sellers aim to target $179.61, the key support.
AbbVie stock
The post Pharma Stock Analysis: Pfizer Bristol-Myers Squibb AbbVie could be updated as new information becomes available
